In addition, we found that the expression of 4 immune checkpoints, including PD-1 (PDCD1), PD-L1 (CD274), and CTLA-4 was significantly upregulated in the low-risk group (Figure 6D), suggesting a potential role of the signature model in predicting immune responses to immunotherapy in BC patients. This evidence concerns the gene CTLA4 and breast cancer.